Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Rating) COO Jian Xie sold 1,269 shares of Fulgent Genetics stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $53.38, for a total value of $67,739.22. Following the completion of the transaction, the chief operating officer now directly owns 329,701 shares in the company, valued at $17,599,439.38. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Fulgent Genetics stock opened at $55.49 on Thursday. The stock’s fifty day moving average is $57.97 and its 200-day moving average is $71.54. The firm has a market capitalization of $1.68 billion, a PE ratio of 3.75 and a beta of 1.55. Fulgent Genetics, Inc. has a 12-month low of $47.65 and a 12-month high of $112.00.
Fulgent Genetics (NASDAQ:FLGT – Get Rating) last announced its earnings results on Tuesday, May 3rd. The company reported $5.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.86 by $1.22. The company had revenue of $320.30 million for the quarter, compared to analyst estimates of $300.50 million. Fulgent Genetics had a return on equity of 41.13% and a net margin of 48.32%. Fulgent Genetics’s revenue for the quarter was down 10.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.51 earnings per share. As a group, equities analysts anticipate that Fulgent Genetics, Inc. will post 5.95 earnings per share for the current fiscal year.
FLGT has been the topic of several analyst reports. Oppenheimer dropped their price objective on Fulgent Genetics from $141.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, January 25th. Piper Sandler lowered their price target on Fulgent Genetics from $85.00 to $70.00 in a report on Sunday. StockNews.com initiated coverage on Fulgent Genetics in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Zacks Investment Research lowered Fulgent Genetics from a “buy” rating to a “hold” rating in a research report on Monday, May 9th.
About Fulgent Genetics (Get Rating)
Fulgent Genetics, Inc, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests.
- Get a free copy of the StockNews.com research report on Fulgent Genetics (FLGT)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.